NASUS PHARMA LIMITED (NSRX)

A massive technology player is announcing its first quarterly earnings and could shake up the entire stock market in the process.

Oops, something went wrong · The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link.

SpaceX stock whipsawed through a volatile week, swinging from an all-time low to a sharp rebound and closing at a new low, as investors braced for the newly public company's first earnings report and a major share unlock.

The last earnings report on July 30 showed earnings per share of 37 cents, beating the estimate of -7 cents. With 6.85M shares outstanding, the current market capitalization sits at 387.15M.

Laidlaw Retierates Buy Rating on Nasus Pharma (NSRX) with $22 Price Target This morning, NSRX announced Brendan O’Grady has been appointed the new CEO of Nasus Pharma and after the news release, we spoke with Mr. O’Grady. Our takeaway is this is a very positive development for NSRX as the ...